Table 2.
Serum antibody and virus titers after heterotypic challenge with A/CA/4/09 (H1N1).
| Vaccine Group | Mean Virus Titer (log10 TCID50/ml) [#(+)/total] | Mean Serum HAI Antibody Titer (range) | ||||
|---|---|---|---|---|---|---|
| 3 dpca | 5 dpc | 14 dpvb | 17 dpc | |||
| SD-LAIV (H1N1) | CA09 (H1N1) | SD-LAIV (H1N1) | CA09 (H1N1) | |||
| CA09 Aerosol | <1 | <1 | <10 | 4267 (2560–10240) | <10 | 1707 (1280–2560) |
| CA09 IN | <1 | <1 | <10 | 2133 (1280–2560) | <10 | 1173 (640–1280) |
| SD-LAIV Aerosol | 4.3±0.70 (3/3) | <1* | 400 (160–640) | <10 | 640 | 1387 (640–2560) |
| SD-LAIV IN | 4.4±0.80 (3/3) | <1* | 427 (160–640) | <10 | 747 (320–1280) | 1067 (640–1280) |
| PBS Aerosol | 6.0±0.58 (3/3) | 5.4±0.29 (3/3) | <10 | <10 | <10 | 3840 (1280–10240) |
a
days post challenge with CA09; n=3/group
b
days post vaccination; n=3/group
c
limit of detection
*
indicates statistically significant differences compared to the PBS aerosol group (p<0.05, repeated measures ANOVA).